New Pick: Predictive Technology Group, Inc. (OTCMKTS: PRED)
There are revolutions in play right now, and even though the market sometimes feels like a minefield, it’s best to avoid watching too much CNBC. It can be distracting.
For example, did you know the gene-based therapy and diagnostic space is expected to ramp to 8.73B by 2019 in coming years at a CAGR of nearly 25pct?
How about this one… One of the emerging leaders in that space is floating at a pps 1.75 and showing some very promising technicals.. Interested?
Symbol: PRED
Company: PREDictive Technology Group, Inc.
Quote: http://finance.yahoo.com/q?s=PRED
Latest News: http://finance.yahoo.com/q/h?s=PRED+Headlines
Company Website: http://www.PREDictivetechnologygroup.com
Key Points:
- PRED is an emerging leader in gene-based companion diagnostics, which is a boom in the making.
- PRED is seeing rising volume off key support, affirming the critical levels necessary to technically support an argument for imminent share price appreciation.
- PRED is coming off an RSI trough under 30, pointing to a massively oversold stock now heading back the other way.
- PRED just recorded a MACD Bullish reversal, suggesting a technical change in trend.
PRED, through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.
The company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases' onsets and progressions.
PRED's subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to prevent and treat diseases effectively.
Companion Diagnostics Market is expected to be worth us-d 8.7B by 2019. We live in the era of the genetic revolution, just as Jay Gatsby lived in the era of the electricity revolution. The big thing going on now is the way we can change our outcome distribution in any health-related cause by dint of a deeper understanding of our DNA moorings.
According to Global Trends & Forecasts, the polymerase contribution to the global companion diagnostics market is “expected to ramp the field to reach u-sd 8,730.7 million by 2019 from u-sd 3136.9 million in 2014, at a CAGR of 22.7pct during the forecast period (2014 to 2019).”
PRED is specifically starting to see interest because of its recent aggressiveness in the space. PRED had occasion to announce within the past month that the Company completed a key acquisition (of ReNovo Biotech, Inc.), establishing a new wholly-owned subsidiary called PREDictive Biotech, Inc. (See Full Press Release Here).
The acquisition provides PRED access to ReNovo Biotech's cellular, tissue, biomaterial and regenerative medicine products and product candidates. Also, PRED will gain access to ReNovo's distribution channels, including access to customers from a recent signing of a private label agreement. ReNovo has additional private label agreements pending for future implementations.
That’s a major leg up.
In addition, PRED announced recently that its subsidiary, Predictive Therapeutics, received a 'Notice of Allowance' from the United States Patent and Trademark Office. (See Full Press Release Here). According to the USPTO. “if, on examination, it appears that the applicant is entitled to a patent under the law, a notice of allowance will be sent to the applicant.”
That suggests an IP element to the valuation that does not appear to be in the current price, further supporting a coming appreciation.
As a result, shares are starting to get a stronger volume play on the tape, and holding key support. This is a critical signal. The key level is the $1 area. The stock dipped and hit that for the third time in the past year, and it held on strong volume and sent the stock 75% higher over the next month.
Given the market segment, this one looks like a no-brainer as far as a major speculative opportunity with the potential to provide some huge upside.
About PRED
PRED (Predictive Technology Group, Inc.), through its subsidiary, PREDictive Therapeutics, engages in the commercialization of therapeutics leveraged by proprietary gene-based companion diagnostics for the treatment of serious and debilitating diseases.
PRED primarily offers EndoRisk, a companion diagnostic/genetic test for endometriosis.
PRED is also developing NHP-07, a pharmaceutical/therapeutic candidate for the treatment of endometriosis; genetic scoliosis test for the diagnosis of scoliosis; and test for degenerative disc disease.
PRED was founded in 2005 and is based in Salt Lake City, Utah.
So, start your DD now and get ready for solid action !
